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Background: The efficiency of high-density-lipoprotein (HDL) to efflux cholesterol 
contributes to the reverse cholesterol transport (RCT) pathway as one of HDL’s proposed 
functions, and depends on the ability of HDL to uptake cholesterol. We aimed to investigated 
cholesterol uptake capacity (CUC) by a newly developed assay in samples from the 
MASHAD (Mashhad-Stroke and Heart-Atherosclerotic-Disorders) cohort study.  
Method: The study population comprised 153 individuals developed CVD diagnosed by a 
specialist cardiologist, over 6-years of follow-up, and 350 subjects without CVD. We used a 
modified CUC method to evaluate the functionality of HDL in serum samples.  
Result: The CUC assay was highly reproducible with values for inter- and intra- assay 
variation of 13.07 and 6.65, respectively. The mean serum CUC was significantly lower in 
the CVD group compared to control (p=0.01). Although, there were no significant differences 
in serum HDL-C between the groups and there was no significantly association with risk of 
progressive CVD. Multivariate logistic regression analysis showed that there was a 
significantly negative association between CUC and risk of CVD after adjustment for 
confounding parameters (OR=0.57, 95%CI=0.38–0.87, P=0.009).  The CUC was also 
inversely and independently associated with the risk of CVD event using Cox-proportional 
hazards models analysis (HR=0.62; 95%CI=0.41-0.94, P=0.02). We determined the optimum 
cut-off value of 1.7 a.u for CUC in the population. Furthermore, the CUC value was 
important in determining the CVD risk stratification derived from data mining analysis. 
Conclusions: Reduced HDL functionality, as measured by CUC, appears to predict CVD in 
population sample from north-eastern Iran.  
Keywords: cholesterol uptake capacity (CUC), HDL function, cardiovascular disease 








The importance of high-density lipoprotein (HDL) functionality rather than its concentration 
has been emphasised in the prediction of cardiovascular disease (CVD) (1, 2). Although, 
many studies have demonstrated inverse associations between serum HDL cholesterol 
concentrations and CVD risk (1, 3), clinical trials of HDL-raising agents such as niacin and 
CETP (cholesteryl ester transfer protein) inhibitor have been failed to support the effects of 
HDL-raising on improved CVD outcomes (4-7). More recent attention has therefore focused 
on the various functions of HDL including antioxidant, anti-inflammatory, and reverse 
cholesterol transport (RCT) (8) that may be related to its athero-protective effects.  Blood 
lipids accumulate in tissue macrophages within the arterial intima during atherogenesis, and 
HDL promotes cholesterol removal from lipid-laden macrophages (9).  A measure of the 
cholesterol-efflux capacity (CEC) has been reported to be inversely related to the incidence 
of cardiovascular events (10, 11). Returning to the hypothesis that concerns the association 
between CVD and HDL focused on the concept of the functionality of HDL instead of 
plasma concentrations, in specific cellular cholesterol efflux (12). As HDL is a pleiotropic 
particle with a variety of properties, its functions have been difficult to evaluate in human 
studies. Although the measurement of HDL cholesterol efflux capacity has been exploited in 
various clinical studies in the case of CVD risk prediction, cell-based assays may have 
several limitations such as heterogeneity of applied cells, standardization, and experimental 
variability. The efficiency of HDL to efflux cholesterol from macrophages through the RCT 
pathway may be an important function of HDL (13) and it depends on the ability of HDL to 
act as an acceptor of cholesterol. Measurement of cholesterol uptake capacity (CUC) is a 
newly developed cell-free, sensitive, and high-throughput assay that reflects the functionality 
of HDL without using radio-isotope labelling and cells (14). Toh et al. (2019) evaluated HDL 
function through the cell-free CUC method in patients treated with coronary stents, 
mentioned that impaired HDL function might anticipate stent failure (15). The research has 
tended to focus on qualitative rather than a quantitative assessment of HDL to improve the 
prediction of cardiovascular and atherosclerosis clinical outcomes. 
Additionally, there have been limited data from cohort study on the association between HDL 
functionality and CVD risk. Therefore, for the first time, this a cohort study aimed to use a 
cell-free assay that evaluates CUC and also its optimal threshold to assess HDL function and 
CVD risk.  
Materials and Methods 
Patient samples 
The MASHAD cohort study (Mashhad Stroke and Heart Atherosclerotic Disorder) is a 
northeastern population of Iran that started in 2010 with 35 to 65 years old participants 
without cardiovascular disease (CVD), stroke, and peripheral arterial disease. The follow-up 
examinations of this study being undertaken every 3 years. Our study comprised three 
hundred and fifty healthy randomized individuals without clinical cardiovascular disease and 
153 subjects without CVD at baseline who then developed CVD outcomes over 6 years of 
follow-up who were recruited as part of the MASHAD cohort study. The diagnosis of CVD 
was assessed based on medical interviews, physical examination by two cardiologists using 
investigations that included: angiography, CT angiography, and ETT over the 6-years 
duration of follow-up. There is no perfect and complete information about the use of lipid-
lowering drugs by patients and healthy individuals. The following anthropometric, 
demographic, and experimental parameters were measured; fasting blood glucose (FBG), 
blood pressure measurements (BP), smoking status, and lipid profile (TC, TG, HDL-C, and 
LDL-C). Informed consent was terminated by all participants and reflected approval by the 
Ethics Committee of the Mashhad University of Medical Sciences (IR. MUMS. Medical. rec. 
1386.250) and the Ethics Committee of the Birjand University of Medical Science (IR. 
BUMS. rec. 1398.51).  
Reagents and materials 
The anti-apoA1 antibody (clone311, catalog number MIA1402) and fetal bovine serum (FBS) 
were purchased from Thermo Scientific. The methyl-β-cyclodextrin was purchased from 
Sigma-Aldrich. BODIPY-cholesterol was purchased from Avanti Polar Lipids. Stock 
solutions of BODIPY-cholesterol were prepared by dissolving each reagent in DMSO 
(dimethyl sulfoxide) at 0.5 mmol/L, and the solutions were stored at −20 °C. PBS (Phosphate 
Buffered Saline) tablets were provided from Sigma-Aldrich that the method of preparation 
was as follows: dissolving one tablet of PBS buffer in 1 liter of deionized water resulting 
in140 mM NaCl, 10 mM phosphate buffer, and 3 mM KCl, pH 7.4 at 25°C. Casein as 
blocking buffer, Polyethylene glycol (PEG) 6000, and Tris HCl were purchased from Merck. 
The stock solution of the liposome, as a regular component of the reaction buffer, was made 
from 12.5 mmol/L cholesterol, 25 mmol/L hydrogenated soy phosphatidylcholine, and 12.5 
mmol/L 1,2-dimyristoylsn- glycerol-3-phosphoglycerol.  
Preparation of the HDL from human serum 
To remove apoB-containing lipoproteins, 100 μl of each serum sample was mixed with 20 μl 
of 45% polyethylene glycol (PEG) 6000 in Tris HCL 0.2 M. Then the serum vortex mixing 
and kept at room temperature for 15 min. The samples were then centrifuged at 10,000 rpm 
for 30 min at 4°C and the supernatant was collected as the HDL fraction (apoB-depleted 
serum).  
Cholesterol uptake capacity assay 
We used a modified cholesterol uptake capacity (CUC) method in our study (14). There are 
three principal steps in this method: (1) preparation of the plate containing the antibody; (2) 
preparing the serum mixture; (3) cholesterol uptake capacity measurement. At first, 100 μl of 
5 μg/mL of the antiapoA1 antibody (clone 311) in PBS, pH 7.4, was added to each well of 
the black microplate (96-well). After incubation overnight at 4 °C, the antibody solutions 
were removed and PBS containing 2% casein solution was added as the blocking buffer and 
incubated at 37 °C for 2 hours. The blocking buffer was removed and the well washed with 
PBS two times. Then 10 μl of each ApoB-depleted serum sample was incubated with 100 μl 
of 5μM BODIPY-cholesterol in PBS containing 2% BSA and 0.8% liposome stock solution. 
Followed by shaking microtubes in an incubator (280 rpm, 37 ° C) for about 20 hours, 100 
μL of the apoB-depleted serum mixture was transferred into the wells that were coated by an 
antibody.  The plate was incubated at 37 °C for 3 hours at 350 rpm. Then, the wells were 
washed with 200 μL PBS five times, and 100 μL of 20 mmol/L cyclodextrin in PBS was 
added to enhance the fluorescence signal derived from BODIPY-cholesterol. After the plate 
was incubated at 25 °C for 30 seconds at 300 rpm, the fluorescence intensity was measured at 
535 nm with excitation at 485 nm on the microplate reader.  
We expressed the cholesterol uptake capacity as CUC % or the percent of BODIPY-
cholesterol uptake by HDL (arbitrary unit or a.u was defined for CUC value). This parameter 
was calculated by subtracting the background signal from the BODIPY-cholesterol uptake 
detected for the apoB-depleted serum samples after washing, divided by BODIPY-cholesterol 
signals for the same at zero-time. Also, the CUC value of each sample was normalized with 
its HDL-C concentration.  
Statistics analysis 
SPSS version 20 (IBM Corp, 2011), MedCalc Statistical Software version 16.8 (Bvba, 
Belgium), and SAS software (JMP Pro 13) were used in this study. Assessment of normality 
parameters was used by Kolmogorov-Smirnov (K-S) test. The T-test for normally distributed 
parameters and chi-square for categorical one was utilized to assess the relationship between 
the baseline features of individuals in the studied populations. Univariate and multivariate 
logistic regression analyses was used to examine the association of the CUC and the risk of 
CVD in the baseline serum samples. P values were considered statistically significant if less 
than 0.05 (<0.05). Moreover, we determined the strength of our study by odds ratio (OR) 
with a confidence interval (CIs) of 95%. MedCalc Statistical Software was used to compare 
baseline serum CUC changes (higher and lower than cut-off) in serum samples until the 
development of clinical CVD was undertaken using Cox proportional hazards models as 
predictors of clinical CVD.  
Data mining analysis was performed using JMP Pro 13 (SAS software). We determined the 
Log-value which is equal to –log (p-value from the Chi-square) of the studied 
cardiometabolic risk factors to assigning the CVD risk stratification. A nominal logistic fit for 
CVD was performed to show the efficient characteristics in the model. A dividing system 
using the decisions tree approach, a multivariate technique was used for both data exploration 
and prediction, was used to predictive and specialized modelling outputs a flowchart-like 
structure. The model was divided into two groups at 5 split layers to produce the most 
division into five subgroups that were as possible for the CVD risk. Scatterplot Matrix was 
depicted for determining the correlation of lipid profile with cholesterol uptake capacity using 
data mining analysis. 
Result 
Clinical characteristics of the population 
The study population sample included 153 individuals without CVD at baseline who then 
developed CVD over 6 years of follow up (CVD group) (76 females (28.4%), aged 53.79 ± 
6.9yrs.) and 350 samples without CVD (192 females (71.6%), aged 48.9 ± 7.8 yrs.). The 
clinical characteristics and lipid profile of the participants at the baseline of the MASHAD 
study cohort have been summarized in Table 1.  
Relationship of cholesterol uptake capacity with the risk of incident CVD  
We evaluated the association between cholesterol uptake capacity (CUC) with cardiovascular 
event risk by measuring the fluorescence intensity of the labelled cholesterol. The parameter 
was determined to investigate HDL functionality in serum samples including the percent of 
BODIPY-cholesterol uptake by apoB depleted sample (CUC %) that was normalized with 
HDL-C concentration. The mean and range of the CUC value in the MASHAD study 
population were equal to 1.18 (0.11-3.4). Our analysis showed that there was a significant 
difference in CUC values (p=0.01) between the group with and without incident CVD events. 
In contrast, no significant difference in HDL-C was found between these groups (figure 1).  
As table 2 shows, the mean value of uptake capacity was lower in the CVD group 
(1.07±0.47) compared to healthy individuals (1.21±0.62), p=0.01.  
Subsequently, we examined the association between HDL-C and cholesterol uptake capacity 
and risk of CVD events developed after 6-years follow-up. According to our result, serum 
HDL-C was not significantly associated with the risk of progressive CVD using either 
unadjusted and adjusted models, while a significantly negative association was found 
between CUC serum samples and risk of CVD outcome in the MASHAD study cohort 
(OR=0.64, 95%CI= 0.45–0.908, P=0.012). Multivariate logistic regression analysis showed 
that there was a 38% reduction in CVD risk among individuals with a higher CUC after 
adjustment for confounding parameters including age, sex, BMI, smoking, TG, LDL, TC, 
diabetes, and hypertension history (OR=0.57, 95%CI= 0.38–0.87, P=0.009). Furthermore, the 
cholesterol uptake capacity measurement was exhibited high reproducibility; the inter- and 
intra- assay of the CUC criterion were detected as 13.07 and 6.65, respectively.  
In the Cox proportional-hazards models (Figure2), there was a significant association of 
higher cut-off point for CUC and decrease cardiovascular endpoints (Hazard ratio, 0.64; 95% 
CI, 0.45-0.90, p=0.01). Interestingly, after adjusted traditional risk factors for cardiovascular 
disease, the result showed that cholesterol uptake capacity was independently and inversely 
associated with the incidence of cardiovascular events (HR, 0.62; 95% CI, 0.41-0.94, 
P=0.02). Kaplan–Meier curve was shown for the CUC value in Figure 2. Our analysis 
showed that those with serum levels lower than 1.7 a.u. had a higher risk of cardiovascular 
disease compared to those with higher scores during a 6-years follow-up.  
Data mining analysis 
In line with these evaluations, we use discriminate analysis to explore the potential markers 
that are involved in cardiovascular risk assessments (Table 3). According to data mining 
analysis, age and hypertension history were the most important factors in determining the risk 
of cardiovascular disease.  As the third parameter, the CUC, a measure of HDL functionality, 
was an important factor in assigning the risk of CVD. The effects of CUC and HDL-C level 
simultaneously and diabetic history also affect the risk of a CVD event. It can be seen from 
the data in table 3 that no significant relationship was found between the other parameters 
and cardiovascular disease. A major finding is that applying data mining techniques using 
this kind of data is viable, and determining CUC is of potential clinical value.  
We determined the optimum cut-off point of 1.7 a.u. for cholesterol uptake capacity in the 
MASHAD cohort population using a decision tree derived from data mining analysis. The 
decision tree with 5 layers, identified the various risk factors for CVD was shown in Figure 3. 
Based on our results, in the subgroup with HDL≥35.3 and TG>115, ninety-one percent of 
subjects were classified in the control group (red strip). In a subgroup with HDL<35.3, 
individuals with HDL<23, and CUC<2.37, eighty eight percent of individuals were in the 
case group (blue strip). Meanwhile, the number of the cases was the same as the number of 
the control classes in individuals with HDL≥23, CUC<1.7, and LDL≥129.5. Finally, in a 
subgroup with HDL≥23 and CUC≥1.7, 93% subjects were in the control classes. A scatter 
plot matrix is shown in figure 4, and helps the visualisation of the relationships between each 
pair of response variables like lipid profile and uptake capacity. The narrowness of the ellipse 
reflects the degree of correlation between variables. As indicated, the ellipse of CUC as a 
marker of HDL function and HDL-C level was narrow and diagonally oriented, therefore the 
variables are correlated. But there was no correlation between the CUC and other elements of 
the lipid profile, since the ellipse was fairly round and was not diagonally oriented when 
looking at these other parameters. 
Discussion 
We aimed to assess the potential value of one measure of HDL functionality in new 
diagnostic procedures for cardiovascular disease in the clinical setting rather than HDL 
concentration according to the last literature (16).  Assessing HDL function with current cell-
based assays has some limitations for routine use in the clinic (17). We developed a cell-free 
assay to investigate the capability of HDL to uptake cholesterol in this study. Our findings 
demonstrated a significant independently negative association between HDL functionality 
and the risk of CVD in our cohort study. These results match those observed in earlier studies 
that have been reported in a cohort study indicated that cholesterol efflux capacity (CEC) as a 
function of HDL was independent of HDL-C levels associated with a predictor of coronary 
artery disease (CAD) (11, 18). Among several specified functions of HDL, measurement of 
the CEC that is attributed to the mechanism of RCT is the most important method to investigate 
the anti-atherosclerotic effects of HDL (19). Previous studies have hypothesized that the 
capability of cholesterol efflux of HDL depends essentially on the ability of HDL to uptake 
extra cholesterol from peripheral tissue (20). 
We demonstrate that the mean value of cholesterol uptake capacity (CUC) was lower in the 
CVD group compared to healthy individuals. Thus, it may be suggested that decreased CUC 
as an index of impaired HDL functionality, might be associated with a future cardiovascular 
disease event. This finding supports the first research by Harada et al. (2017) into the study of 
the CUC on 156 subjects which links the cholesterol uptake capacity as a cell-free assay and 
recurrence of coronary lesions. It had been demonstrated that among common risk factors of 
CVD, only CUC remained significantly associated in patients with a controlled LDL 
concentration (14). Their results were in agreement with the findings of the last study, in 
which the logistic regression analysis showed that reduced CUC was independently related to 
neo-atherosclerosis (OR, 0.79; P<0.001) and organization of target lesion revascularization 
(OR, 0.88; P=0.003). According to the study by Toh, there was a significant correlation 
between HDL particle concentration and CUC that was measured using NMR (nuclear 
magnetic resonance spectroscopy). He found that large HDL particles had more association 
with CUC than small ones (18).  
A large and growing body of cohort studies has investigated the cholesterol efflux capacity of 
HDL using ABCA1 up-regulated cells (10, 11, 21). A single cohort study exists in which 
Nagano et al. have described the importance of HDL functionality for targeting coronary 
lesion revascularization within patients who were treated with coronary stents using a cell-
free assay (15). Their result demonstrates that CUC at follow-up optical coherence 
tomography (OCT) was significantly lower in a group who developed neoatherosclerosis 
(NA+) compared to NA- group (Log Rank P<0.001). To our knowledge, our investigation is 
the first to undertake the potential relation between CUC as a marker of HDL functionality 
and hazard ratio of CVD risk in a large prospective cohort study. According to Cox 
proportional-hazards models, those with serum levels lower than 1.7 a.u. have a higher risk of 
cardiovascular disease compared to those with higher scores during a 6-years follow-up (Log 
Rank p<0.003). It seems to be suggesting CUC < 1.7 a.u. is related to the impaired HDL 
function to uptake cholesterol and exposed to the prominent risk of CVD outcomes in a 
population‐based cohort.  
Surprisingly, another important finding, reported for the first time, was that the CUC value 
was the third most important parameter in assessing the CVD risk stratification, derived using 
data mining analysis. The evidence from the decision tree suggests that in the subgroup with 
HDL≥23, 26% of subjects in the CVD group possessed CUC<1.7, while in this subgroup 
6.7% of individuals with CVD had CUC≥1.7. Some of the issues emerging from this finding 
relate specifically to low CUC value and more CVD risk assessment. These findings have 
also argued that not only HDL concentration but also HDL functionality is considered as a 
potent risk factor for CVD.  HDL metabolism may explain the inadequate effect of HDL 
particles on CVD risk stratification. As noted by Hirano (1997), the mutation of cholesterol 
ester transfer protein (CETP), which promotes RCT and results in an increase in HDL-C, 
does not  decrease cardiovascular events (22).  
Finally, several limitations may need to be considered in our study. First, the sample size was 
small compared to the total MASHAD cohort study. The second was the lack of 
apolipoprotein-A1 measurement that can be used for the normalization of CUC. Thirdly, 
HDL functionality is a clinically important factor that is determined by environmental and 
genetic factors that can result in the progression of atherosclerosis and cardio-metabolic 
disorders. Fourthly, there is no perfect and complete information about the use of lipid-
lowering drugs by individuals since they might have an influence on CUC.  Therefore, more 
research needs to be undertaken to explore the association between CUC and cardiovascular 
risk.  
Conclusion: 
This project was undertaken to design and evaluate HDL functionality assessment in the 
MASHAD cohort study by measurement of cholesterol uptake capacity of HDL. Our findings 
suggest that a low uptake capacity or impaired HDL functionality can be used as a potential 
biomarker for the prediction of progressive CVD. Also, we showed that cholesterol uptake 
capacity was independently reverse associated with the prevalence of cardiovascular events. 
The CUC assay is a high-throughput,  high reproducibility, cell-free assay could be used for 
the assessment of CVD risk in clinical settings. 
 
Key funding 
(1) A decreased CUC value was independently reverse associated with the CVD event  
(2) The mean value of CUC was lower in the CVD group compared to healthy individuals  
(3) Neither HDL-C were not significantly associated with the risk of progressing CVD, while 
a significantly negative association was found between CUC at the baseline samples and risk 
of clinical CVD  
(4) The CUC value was the third parameter that is significantly effective in assigning the 
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